• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?

  • — 28 Feb, 2007
AudioMedica News
AudioMedica News
Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?
Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?
00:00 /
RSS Feed
Share
Link
Embed
Steven Grinspoon

Judith Currier

STEVEN GRINSPOON, Massachusetts General Hospital, Boston
COMMENT: JUDITH CURRIER, University of California, Los Angeles

REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Daily administration of an analog of growth hormone releasing factor to HIV patients receiving highly active antiretroviral therapy significantly decreased visceral fat and improved their lipid profiles. This development-stage drug, TH9507, was well tolerated and may help patients reduce central fat accumulation and abnormal lipid profiles, both of which are known cardiovascular risk factors. In addition, decreases in central fat may have a positive effect on patients’ self-image. Steven Grinspoon gave Dan Keller details during the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.

[audio:https://www.audiomedica.com/podcasting/global_health/022607_Grinspoon.mp3]

You may also like...

  • Heidi Larson The New Decade Of Vaccines: Avoiding Public Distrust 14 Jul, 2011
  • Dr Clare Chandler World Malaria Day 2012: Social Solutions Bring Malaria Under Control 24 Apr, 2012
  • Audio Journal of Global Health Issues: Patient Power Best to Manage Diabetes Audio Journal of Global Health Issues: Patient Power Best to Manage Diabetes 20 Apr, 2007
  • Gillian Stresman Locating Asymptomatic Malaria In Africa — New Methods Raise Hopes For Elimination 30 Mar, 2012
  • Previous story Herpes Simplex Therapy Reduces HIV Activity in Co-Infected Patients
  • Next story Audio Journal of Oncology in Advance – March 1st, 2007
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Which Tasks Most Influence Pediatric PT Productivity,…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
  • Home
  • Public Health
  • Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.